These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 16478692)
1. MRI-guided immunotherapy development for multiple sclerosis in a primate. 't Hart BA; Smith P; Amor S; Strijkers GJ; Blezer EL Drug Discov Today; 2006 Jan; 11(1-2):58-66. PubMed ID: 16478692 [TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. 't Hart BA; Hintzen RQ; Laman JD Neurodegener Dis; 2008; 5(1):38-52. PubMed ID: 18075274 [TBL] [Abstract][Full Text] [Related]
3. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). 't Hart BA; Massacesi L J Neuropathol Exp Neurol; 2009 Apr; 68(4):341-55. PubMed ID: 19337065 [TBL] [Abstract][Full Text] [Related]
4. Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis. Blezer EL; Bauer J; Brok HP; Nicolay K; 't Hart BA NMR Biomed; 2007 Apr; 20(2):90-103. PubMed ID: 16948176 [TBL] [Abstract][Full Text] [Related]
5. Modelling of multiple sclerosis: lessons learned in a non-human primate. 't Hart BA; Laman JD; Bauer J; Blezer E; van Kooyk Y; Hintzen RQ Lancet Neurol; 2004 Oct; 3(10):588-97. PubMed ID: 15380155 [TBL] [Abstract][Full Text] [Related]
6. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis. Rotstein Z; Hazan R; Barak Y; Achiron A Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884 [TBL] [Abstract][Full Text] [Related]
8. Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis. Bagnato F; Ohayon JM; Ehrmantraut M; Chiu AW; Riva M; Ikonomidou VN Expert Rev Neurother; 2006 Apr; 6(4):599-612. PubMed ID: 16623658 [TBL] [Abstract][Full Text] [Related]
9. Non-human primate models of experimental autoimmune encephalomyelitis: Variations on a theme. 't Hart BA; Bauer J; Brok HP; Amor S J Neuroimmunol; 2005 Nov; 168(1-2):1-12. PubMed ID: 16023737 [TBL] [Abstract][Full Text] [Related]
10. MRI to predict severe tissue damage in inflammatory lesions in animal models of multiple sclerosis. Brochet B; Dousset V; Deloire M; Boiziau C; Petry KG Brain; 2008 Mar; 131(Pt 3):e92. PubMed ID: 17965047 [No Abstract] [Full Text] [Related]
11. MR in the diagnosis and monitoring of multiple sclerosis: an overview. Rovira A; León A Eur J Radiol; 2008 Sep; 67(3):409-14. PubMed ID: 18434066 [TBL] [Abstract][Full Text] [Related]
12. Measuring brain atrophy in multiple sclerosis. De Stefano N; Battaglini M; Smith SM J Neuroimaging; 2007 Apr; 17 Suppl 1():10S-15S. PubMed ID: 17425728 [TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: common management issues. McDonald E Aust Fam Physician; 1992 Oct; 21(10):1421-4. PubMed ID: 1280093 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. Matsuoka T; Matsushita T; Osoegawa M; Ochi H; Kawano Y; Mihara F; Ohyagi Y; Kira J J Neurol Sci; 2008 Mar; 266(1-2):115-25. PubMed ID: 17950755 [TBL] [Abstract][Full Text] [Related]
16. The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Bolton C Inflammopharmacology; 2007 Oct; 15(5):183-7. PubMed ID: 17943249 [TBL] [Abstract][Full Text] [Related]